论文部分内容阅读
目的探讨沙美特罗替卡松联合噻托溴铵粉吸入剂治疗重度、极重度慢性阻塞性肺疾病(COPD)稳定期患者的临床疗效。方法选取2013年2月—2015年1月双流县第一人民医院收治的重度、极重度COPD稳定期患者100例,随机分为研究组与对照组,各50例。对照组患者予以沙美特罗替卡松治疗,研究组患者在对照组基础上加用噻托溴铵粉吸入剂治疗。观察两组患者临床疗效、治疗前后6min步行距离及不良反应发生情况。结果研究组患者总有效率高于对照组,差异有统计学意义(P<0.05);治疗前两组患者6min步行距离比较,差异无统计学意义(P>0.05),治疗后研究组患6min步行距离长于对照组,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论沙美特罗替卡松联合噻托溴铵粉吸入剂治疗重度、极重度COPD稳定期患者的临床疗效显著,可改善患者临床症状,且不良反应少。
Objective To investigate the clinical efficacy of salmeterol and tiaprost in combination with tiotropium bromide inhaler in the treatment of patients with severe and severe chronic obstructive pulmonary disease (COPD). Methods From February 2013 to January 2015, 100 patients with severe and severe stable COPD admitted to the First People’s Hospital of Shuangliu County were randomly divided into study group and control group, with 50 cases in each group. Patients in the control group were treated with salmeterol and fluticasone. Patients in the study group were treated with tiotropium bromide inhaler on the basis of the control group. The clinical curative effect was observed in both groups. The walking distance and the adverse reactions occurred 6min before and after treatment. Results The total effective rate of the study group was higher than that of the control group (P <0.05). There was no significant difference in the walking distance between the two groups before 6 minutes of treatment (P> 0.05) Walking distance longer than the control group, the difference was statistically significant (P <0.05); two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusions The combination of salmeterol and titaloxime powder with tiotropium powder inhaler in the treatment of patients with severe and very severe stable COPD has significant clinical effect, which can improve the clinical symptoms of patients with less adverse reactions.